
Steven J Siegel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1465476/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers, 2011, 3, 1377-1397.	4.5	3,240
2	Facial Emotion Recognition in Schizophrenia: Intensity Effects and Error Pattern. American Journal of Psychiatry, 2003, 160, 1768-1774.	7.2	659
3	Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia. Nature Medicine, 2006, 12, 824-828.	30.7	528
4	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigation, 2004, 113, 1353-1363.	8.2	371
5	Computerized Neurocognitive Scanning: I. Methodology and Validation in Healthy People. Neuropsychopharmacology, 2001, 25, 766-776.	5.4	344
6	Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. International Journal of Pharmaceutics, 2007, 336, 367-375.	5.2	334
7	Validating γ Oscillations and Delayed Auditory Responses as Translational Biomarkers of Autism. Biological Psychiatry, 2010, 68, 1100-1106.	1.3	275
8	Gamma synchrony: Towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuropharmacology, 2012, 62, 1504-1518.	4.1	244
9	Influenza Promotes Pneumococcal Growth during Coinfection by Providing Host Sialylated Substrates as a Nutrient Source. Cell Host and Microbe, 2014, 16, 55-67.	11.0	209
10	Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigation, 2004, 113, 1353-1363.	8.2	206
11	Varenicline Improves Mood and Cognition During Smoking Abstinence. Biological Psychiatry, 2009, 65, 144-149.	1.3	199
12	Flat Affect in Schizophrenia: Relation to Emotion Processing and Neurocognitive Measures. Schizophrenia Bulletin, 2006, 32, 279-287.	4.3	195
13	Ketamine Modulates Theta and Gamma Oscillations. Journal of Cognitive Neuroscience, 2010, 22, 1452-1464.	2.3	191
14	TRIM Protein-Mediated Regulation of Inflammatory and Innate Immune Signaling and Its Association with Antiretroviral Activity. Journal of Virology, 2013, 87, 257-272.	3.4	189
15	Effect of drug type on the degradation rate of PLGA matrices. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 64, 287-293.	4.3	177
16	Circuit-specific alterations of N-methyl-D-aspartate receptor subunit 1 in the dentate gyrus of aged monkeys Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 3121-3125.	7.1	174
17	Self-face recognition and theory of mind in patients with schizophrenia and first-degree relatives. Schizophrenia Research, 2006, 88, 151-160.	2.0	173
18	GABAB-mediated rescue of altered excitatory–inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Translational Psychiatry, 2012, 2, e142-e142.	4.8	172

#	Article	IF	CITATIONS
19	Working memory deficits predict short-term smoking resumption following brief abstinence. Drug and Alcohol Dependence, 2010, 106, 61-64.	3.2	169
20	Computerized Neurocognitive Scanning: II. The Profile of Schizophrenia. Neuropsychopharmacology, 2001, 25, 777-788.	5.4	157
21	Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. International Journal of Pharmaceutics, 2008, 346, 151-159.	5.2	156
22	Mechanisms of Bacterial Colonization of the Respiratory Tract. Annual Review of Microbiology, 2015, 69, 425-444.	7.3	154
23	Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience, 2007, 144, 239-246.	2.3	151
24	Mouse behavioral endophenotypes for schizophrenia. Brain Research Bulletin, 2010, 83, 147-161.	3.0	150
25	mGluR5-Antagonist Mediated Reversal of Elevated Stereotyped, Repetitive Behaviors in the VPA Model of Autism. PLoS ONE, 2011, 6, e26077.	2.5	146
26	Translational research in medication development for nicotine dependence. Nature Reviews Drug Discovery, 2007, 6, 746-762.	46.4	142
27	Withdrawal from Chronic Nicotine Administration Impairs Contextual Fear Conditioning in C57BL/6 Mice. Journal of Neuroscience, 2005, 25, 8708-8713.	3.6	141
28	Deviance-elicited Changes in Event-related Potentials are Attenuated by Ketamine in Mice. Journal of Cognitive Neuroscience, 2008, 20, 1403-1414.	2.3	137
29	Ketamine Produces Lasting Disruptions in Encoding of Sensory Stimuli. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 315-324.	2.5	134
30	A sexually dimorphic ratio of orbitofrontal to amygdala volume is altered in schizophrenia. Biological Psychiatry, 2004, 55, 512-517.	1.3	125
31	Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. Journal of Microencapsulation, 2005, 22, 773-785.	2.8	123
32	Effects of the α4β2 Partial Agonist Varenicline on Brain Activity and Working Memory in Abstinent Smokers. Biological Psychiatry, 2010, 67, 715-721.	1.3	119
33	Profile of auditory information-processing deficits in schizophrenia. Psychiatry Research, 2009, 165, 27-37.	3.3	117
34	Prognostic Variables at Intake and Long-Term Level of Function in Schizophrenia. American Journal of Psychiatry, 2006, 163, 433-441.	7.2	112
35	Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions. Brain Research, 2009, 1294, 116-127.	2.2	111
36	Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia?. Genes, Brain and Behavior, 2012, 11, 740-750.	2.2	105

#	Article	IF	CITATIONS
37	Effects of Strain, Novelty, and NMDA Blockade on Auditory-Evoked Potentials in Mice. Neuropsychopharmacology, 2003, 28, 675-682.	5.4	103
38	Levels-of-Processing Effect on Frontotemporal Function in Schizophrenia During Word Encoding and Recognition. American Journal of Psychiatry, 2005, 162, 1840-1848.	7.2	100
39	Phosphodiesterase inhibitors: A novel mechanism for receptor-independent antipsychotic medications. Neuroscience, 2004, 129, 101-107.	2.3	98
40	Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E962-70.	7.1	98
41	Olfactory Functioning in Schizophrenia: Relationship to Clinical, Neuropsychological, and Volumetric MRI Measures. Journal of Clinical and Experimental Neuropsychology, 2006, 28, 1444-1461.	1.3	96
42	Parvalbumin Cell Ablation of NMDA-R1 Causes Increased Resting Network Excitability with Associated Social and Self-Care Deficits. Neuropsychopharmacology, 2014, 39, 1603-1613.	5.4	96
43	PDE inhibitors in psychiatry–future options for dementia, depression and schizophrenia?. Drug Discovery Today, 2007, 12, 870-878.	6.4	91
44	Pyramidal Cell Selective Ablation of N-Methyl-D-Aspartate Receptor 1 Causes Increase in Cellular and Network Excitability. Biological Psychiatry, 2015, 77, 556-568.	1.3	89
45	Knockout of <scp>NMDA</scp> Receptors in Parvalbumin Interneurons Recreates Autismâ€Like Phenotypes. Autism Research, 2013, 6, 69-77.	3.8	87
46	The Effects of Ketamine Vary Among Inbred Mouse Strains and Mimic Schizophrenia for the P80, but not P20 or N40 Auditory ERP Components. Neurochemical Research, 2004, 29, 1179-1188.	3.3	85
47	In Vitro–In Vivo Correlations of Scalable PLGA-Risperidone Implants for the Treatment of Schizophrenia. Pharmaceutical Research, 2010, 27, 1730-1737.	3.5	82
48	Synthesis and Characterization of mPEGâ^'PLA Prodrug Micelles. Biomacromolecules, 2005, 6, 2708-2717.	5.4	81
49	Levels-of-processing effect on word recognition in schizophrenia. Biological Psychiatry, 2003, 54, 1154-1161.	1.3	76
50	Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiology of Disease, 2012, 47, 338-346.	4.4	69
51	Effects of social deprivation in prepubescent rhesus monkeys: immunohistochemical analysis of the neurofilament protein triplet in the hippocampal formation. Brain Research, 1993, 619, 299-305.	2.2	67
52	A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience, 2008, 157, 95-104.	2.3	67
53	GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the <i>Fmr1</i> Knockout Mouse Model of Fragile X Syndrome. ENeuro, 2017, 4, ENEURO.0380-16.2017.	1.9	66
54	Effects of Chronic Olanzapine and Haloperidol Differ on the Mouse N1 Auditory Evoked Potential. Neuropsychopharmacology, 2004, 29, 739-746.	5.4	63

#	Article	IF	CITATIONS
55	TLR2 Signaling Decreases Transmission of Streptococcus pneumoniae by Limiting Bacterial Shedding in an Infant Mouse Influenza A Co-infection Model. PLoS Pathogens, 2014, 10, e1004339.	4.7	63
56	Development of an Abbreviated Schizophrenia Quality of Life Scale Using a New Method. Neuropsychopharmacology, 2003, 28, 773-777.	5.4	62
57	Constitutive Activation of Cαs within Forebrain Neurons Causes Deficits in Sensorimotor Gating Because of PKA-Dependent Decreases in cAMP. Neuropsychopharmacology, 2007, 32, 577-588.	5.4	62
58	Zelrixâ,"¢: A Novel Transdermal Formulation of Sumatriptan. Headache, 2009, 49, 817-825.	3.9	62
59	Effects of Nicotine Vary Across Two Auditory Evoked Potentials in the Mouse. Biological Psychiatry, 2007, 61, 23-30.	1.3	59
60	In vitro and in vivo demonstration of risperidone implants in mice. Schizophrenia Research, 2008, 98, 66-78.	2.0	59
61	MeCP2+/â^' mouse model of RTT reproduces auditory phenotypes associated with Rett syndrome and replicate select EEG endophenotypes of autism spectrum disorder. Neurobiology of Disease, 2012, 46, 88-92.	4.4	56
62	From provocation to aggression: the neural network. BMC Neuroscience, 2017, 18, 73.	1.9	56
63	Antipsychotic-Like Properties of Phosphodiesterase 4 Inhibitors: Evaluation of 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with Auditory Event-Related Potentials and Prepulse Inhibition of Startle. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 230-239.	2.5	55
64	Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains. Brain Research, 2003, 992, 85-95.	2.2	54
65	Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism Behavioral Neuroscience, 2015, 129, 389-398.	1.2	54
66	Association of Enhanced Limbic Response to Threat With Decreased Cortical Facial Recognition Memory Response in Schizophrenia. American Journal of Psychiatry, 2010, 167, 418-426.	7.2	53
67	PDE-4 Inhibition Rescues Aberrant Synaptic Plasticity in <i>Drosophila</i> and Mouse Models of Fragile X Syndrome. Journal of Neuroscience, 2015, 35, 396-408.	3.6	53
68	Mice with subtle reduction of NMDA NR1 receptor subunit expression have a selective decrease in mismatch negativity: Implications for schizophrenia prodromal population. Neurobiology of Disease, 2015, 73, 289-295.	4.4	52
69	Effect of retrieval effort and switching demand on fMRI activation during semantic word generation in schizophrenia. Schizophrenia Research, 2008, 99, 312-323.	2.0	51
70	Mouse Model of Chromosome 15q13.3 Microdeletion Syndrome Demonstrates Features Related to Autism Spectrum Disorder. Journal of Neuroscience, 2015, 35, 16282-16294.	3.6	51
71	A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology. Neuropsychopharmacology, 2020, 45, 1411-1422.	5.4	51
72	Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials. Neuroscience, 2005, 133, 729-738.	2.3	49

#	Article	IF	CITATIONS
73	Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event–related potential and evoked gamma. Neuroscience, 2007, 144, 1314-1323.	2.3	49
74	Animal Models of Psychosis: Current State and Future Directions. Current Behavioral Neuroscience Reports, 2014, 1, 100-116.	1.3	49
75	Surgically Implantable Long-term Antipsychotic Delivery Systems for the Treatment of Schizophrenia. Neuropsychopharmacology, 2002, 26, 817-823.	5.4	47
76	Lysosomal iron modulates NMDA receptor-mediated excitation via small GTPase, Dexras1. Molecular Brain, 2016, 9, 38.	2.6	47
77	Mismatch negativity in preclinical models of schizophrenia. Schizophrenia Research, 2018, 191, 35-42.	2.0	45
78	A Unique Iontophoretic Patch for Optimal Transdermal Delivery of Sumatriptan. Pharmaceutical Research, 2007, 24, 1919-1926.	3.5	43
79	Chronic ketamine impairs fear conditioning and produces long-lasting reductions in auditory evoked potentials. Neurobiology of Disease, 2009, 35, 311-317.	4.4	43
80	mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia. Molecular Psychiatry, 2020, 25, 750-760.	7.9	39
81	The Role of Nicotine in Schizophrenia. International Review of Neurobiology, 2015, 124, 23-78.	2.0	37
82	Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism. Pharmacology Biochemistry and Behavior, 2019, 181, 93-100.	2.9	37
83	Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models. Frontiers in Behavioral Neuroscience, 2016, 10, 136.	2.0	36
84	Constitutive activation of the G-protein subunit Gαs within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical <i>Arc</i> mRNA expression. Learning and Memory, 2008, 15, 75-83.	1.3	35
85	Animal models and measures of perceptual processing in Schizophrenia. Neuroscience and Biobehavioral Reviews, 2013, 37, 2092-2098.	6.1	34
86	Sensorimotor Gating Deficits in Transgenic Mice Expressing a Constitutively Active Form of Gsα. Neuropsychopharmacology, 2004, 29, 494-501.	5.4	33
87	Prospective MEG biomarkers in ASD: pre-clinical evidence and clinical promise of electrophysiological signatures. Yale Journal of Biology and Medicine, 2015, 88, 25-36.	0.2	32
88	Development of a New Genetic Model for Absence Epilepsy: Spike-Wave Seizures in C3H/He and Backcross Mice. Journal of Neuroscience, 2005, 25, 3452-3458.	3.6	31
89	A placebo-controlled trial of modafinil for nicotine dependence. Drug and Alcohol Dependence, 2008, 98, 86-93.	3.2	31
90	Convergence of circuit dysfunction in ASD: a common bridge between diverse genetic and environmental risk factors and common clinical electrophysiology. Frontiers in Cellular Neuroscience, 2014, 8, 414.	3.7	31

#	Article	IF	CITATIONS
91	Clearance of Pneumococcal Colonization in Infants Is Delayed through Altered Macrophage Trafficking. PLoS Pathogens, 2015, 11, e1005004.	4.7	31
92	Ketamine exposure in adult mice leads to increased cell death in C3H, DBA2 and FVB inbred mouse strains. Drug and Alcohol Dependence, 2008, 92, 217-227.	3.2	30
93	EEG biomarkers of target engagement, therapeutic effect, and disease process. Annals of the New York Academy of Sciences, 2015, 1344, 12-26.	3.8	30
94	Corticosterone Modulates Auditory Gating in Mouse. Neuropsychopharmacology, 2006, 31, 897-903.	5.4	29
95	A rapid method for creating drug implants: Translating laboratoryâ€based methods into a scalable manufacturing process. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2010, 93B, 562-572.	3.4	28
96	Symptom and demographic profiles in first-episode schizophrenia. Schizophrenia Research, 2004, 67, 185-194.	2.0	24
97	Role of β2-containing nicotinic acetylcholine receptors in auditory event-related potentials. Psychopharmacology, 2009, 202, 745-751.	3.1	22
98	The nature and consequences of cognitive deficits among tobacco smokers with HIV: a comparison to to to to to to	2.1	22
99	Neurocognitive Performance and Clinical Changes in Olanzapine-Treated Patients with Schizophrenia. Neuropsychopharmacology, 2003, 28, 2029-2036.	5.4	21
100	Patient Attitudes towards Surgically Implantable, Long-Term Delivery of Psychiatric Medicine. Neuropsychopharmacology, 2004, 29, 960-968.	5.4	21
101	Brain activity and emotional processing in smokers treated with varenicline. Addiction Biology, 2013, 18, 732-738.	2.6	21
102	The scent of salience — Is there olfactory-trigeminal conditioning in humans?. NeuroImage, 2013, 77, 93-104.	4.2	21
103	Nicotine Receptor Subtype-Specific Effects on Auditory Evoked Oscillations and Potentials. PLoS ONE, 2012, 7, e39775.	2.5	21
104	Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expression. Psychopharmacology, 2013, 227, 639-649.	3.1	19
105	Mice expressing constitutively active Gsα exhibit stimulus encoding deficits similar to those observed in schizophrenia patients. Neuroscience, 2006, 141, 1257-1264.	2.3	18
106	Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits. Psychopharmacology, 2006, 190, 201-211.	3.1	18
107	Mouse model predicts effects of smoking and varenicline on event-related potentials in humans. Nicotine and Tobacco Research, 2010, 12, 589-597.	2.6	18
108	Activation of the Mitogen-activated Protein Kinase, Slt2p, at Bud Tips Blocks a Late Stage of Endoplasmic Reticulum Inheritance in Saccharomyces cerevisiae. Molecular Biology of the Cell, 2010, 21, 1772-1782.	2.1	17

#	Article	IF	CITATIONS
109	Release of highly hydrophilic drugs from poly(ϵ aprolactone) matrices. Journal of Applied Polymer Science, 2008, 107, 3149-3156.	2.6	15
110	Male and female mice differ for baseline and nicotine-induced event related potentials Behavioral Neuroscience, 2008, 122, 982-990.	1.2	15
111	Novel Environment and GABA Agonists Alter Event-Related Potentials in <i>N</i> -Methyl-d-aspartate NR1 Hypomorphic and Wild-Type Mice. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 308-318.	2.5	15
112	cAMP Response Element Binding Protein Phosphorylation in Nucleus Accumbens Underlies Sustained Recovery of Sensorimotor Gating Following Repeated D2-Like Receptor Agonist Treatment in Rats. Biological Psychiatry, 2011, 69, 288-294.	1.3	15
113	Protocadherin 10 alters \hat{I}^3 oscillations, amino acid levels, and their coupling; baclofen partially restores these oscillatory deficits. Neurobiology of Disease, 2017, 108, 324-338.	4.4	15
114	The Drosophila DmGluRA is required for social interaction and memory. Frontiers in Pharmacology, 2013, 4, 64.	3.5	14
115	Parvalbumin Cell Ablation of NMDA-R1 Leads to Altered Phase, But Not Amplitude, of Gamma-Band Cross-Frequency Coupling. Brain Connectivity, 2019, 9, 263-272.	1.7	12
116	Evaluation ofin vitro release andin vivo efficacy of mPEG-PLA-haloperidol conjugate micelle-like structures. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2007, 83B, 422-430.	3.4	11
117	Predator odor modulates auditory event-related potentials in mice. NeuroReport, 2009, 20, 1260-1264.	1.2	11
118	Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 93, 84-92.	4.8	11
119	Sociability development in mice with cellâ€specific deletion of the NMDA receptor NR1 subunit gene. Genes, Brain and Behavior, 2020, 19, e12624.	2.2	11
120	The Electrophysiological Signature of Motivational Salience in Mice and Implications for Schizophrenia. Neuropsychopharmacology, 2012, 37, 2846-2854.	5.4	10
121	Aberrant functional connectivity between reward and inhibitory control networks in pre-adolescent binge eating disorder. Psychological Medicine, 2023, 53, 3869-3878.	4.5	10
122	Attitudes of patients and family members towards implantable psychiatric medication. Schizophrenia Research, 2008, 105, 279-286.	2.0	9
123	Nicotine normalizes event related potentials in COMT-Val-tg mice and increases gamma and theta spectral density Behavioral Neuroscience, 2012, 126, 332-343.	1.2	9
124	Amygdala activity associated with social choice in mice. Behavioural Brain Research, 2017, 332, 84-89.	2.2	9
125	Regional gray matter abnormalities in pre-adolescent binge eating disorder: A voxel-based morphometry study. Psychiatry Research, 2022, 310, 114473.	3.3	9
126	Electroencephalographic Changes Following Direct Current Deep Brain Stimulation of Auditory Cortex. Neurosurgery, 2013, 72, 267-275.	1.1	7

#	Article	IF	CITATIONS
127	High-beta/low-gamma frequency activity reflects top-down predictive coding during a spatial working memory test. Experimental Brain Research, 2019, 237, 1881-1888.	1.5	7
128	Translating basic science to improve pharmacotherapy for nicotine dependence. Nicotine and Tobacco Research, 2007, 9, 583-598.	2.6	6
129	Delivery Systems and Dosing for Antipsychotics. Handbook of Experimental Pharmacology, 2012, , 267-298.	1.8	6
130	Electroencephalographic and early communicative abnormalities in Brattleboro rats. Physiological Reports, 2013, 1, e00100.	1.7	6
131	Antipsychotic Dosing and Drug Delivery. Current Topics in Behavioral Neurosciences, 2010, 4, 141-177.	1.7	5
132	Early life social instability stress causes lasting cognitive decrement and elevated hippocampal stress-related gene expression. Experimental Neurology, 2022, 354, 114099.	4.1	5
133	Increased patient autonomy through long-term antipsychotic delivery systems for the treatment of schizophrenia. Expert Review of Neurotherapeutics, 2002, 2, 771-773.	2.8	4
134	Extended release drug delivery strategies in psychiatry: theory to practice. Psychiatry, 2005, 2, 22-31.	0.3	4
135	Frequency-specific medial septal nucleus deep brain stimulation improves spatial memory in MK-801-treated male rats. Neurobiology of Disease, 2022, 170, 105756.	4.4	4
136	Patient and family attitudes toward schizophrenia treatment. Current Psychiatry Reports, 2004, 6, 283-288.	4.5	3
137	Metabotropic Glutamate Receptor 5 as a Point of Convergence for Models of Obsessive-Compulsive Disorder and Autism Spectrum Disorder. Biological Psychiatry, 2016, 80, 504-506.	1.3	3
138	Pyramidal cell-selective GluN1 knockout causes impairments in salience attribution and related EEG activity. Experimental Brain Research, 2018, 236, 837-846.	1.5	3
139	Extended-Release Intramuscular Naltrexone. Drugs, 2006, 66, 1752-1754.	10.9	2
140	Psychiatric health care provider attitudes towards implantable medication. Psychiatry Research, 2010, 177, 167-171.	3.3	2
141	Resurgence of Long-Acting Antipsychotic Formulations. Current Psychiatry Reports, 2010, 12, 276-278.	4.5	1
142	What Can We Expect From Long-Acting Formulations for Schizophrenia?. Current Psychiatry Reports, 2011, 13, 243-244.	4.5	1
143	Capacity, Confidentiality and Consequences: Balancing Responsible Medical Care With Mental Health Law. Current Psychiatry Reports, 2013, 15, 380.	4.5	1
144	PSYCHOSIS AND SCHIZOPHRENIA. , 2009, , 797-815.		1

#	Article	IF	CITATIONS
145	Male and female mice differ for baseline and nicotine-induced event related potentials Translational Issues in Psychological Science, 2014, 1, 35-46.	1.0	0